Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
- PMID: 16782907
- DOI: 10.1200/JCO.2006.05.9709
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
Comment on
-
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8. doi: 10.1200/JCO.2005.03.7804. J Clin Oncol. 2006. PMID: 16782912 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
